The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early and locally advanced non-small-cell lung cancer (NSCLC) were published in August 2025 and were adapted in November 2025 according to previously established standard methodology...
H. Hayashi, A. Zer, H. Kenmotsu et al.· ESMO Open· 0 citations
BACKGROUND
Izalontamab brengitecan (iza-bren) is a first-in-class bispecific antibody-drug conjugate targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) and has shown antitumour activity in EGFR-mutated non-small-cell lung cancer (NSCLC). We compared iza-bren with plati...
Shao-Dong Hong, Ting Zhou, Xue Hou et al.· The Lancet· 0 citations
Iza-bren significantly improved progression-free survival versus chemotherapy, and median progression-free survival assessed by Blinded Independent Central Review was 8·2 months (95% CI 6·9-8·6) versus 4·0 months (2·9-4·3; HR 0·41 [95% CI 0·33-0·53).
B. Lan, Ye-Hui Shi, Xi-Ying Shao et al.· The Lancet· 0 citations
Importance
Trastuzumab rezetecan (SHR-A1811) has demonstrated encouraging antitumor activity in a global phase 1 trial involving heavily pretreated patients with erythroblastic oncogene B (ERBB2)-low metastatic breast cancer.
Objective
To compare trastuzumab rezetecan vs physician's choice of chemotherapy in patients...
Y. Fan, Yun-Jiang Liu, Yong-Sheng Wang et al.· Journal of the American Medi...· 1 citation
The oral–lung axis describes microbial and inflammatory exchange between the oral cavity and the lower respiratory tract. Its relevance to lung cancer is supported by the detection of oral-associated taxa in lower-airway samples, epidemiological links between periodontal disease and lung cancer risk, and experimental e...
Xiang-Liang Liu, Guan-Ran Ding, Jin Lu et al.· Frontiers in Immunology· 0 citations
MMX and MVX are independently associated with incident AD, supporting the clinical relevance of metabolic health monitoring in neurodegeneration risk stratification.
Guan-Ran Ding, Yu-Ting Liu, Yi-Xin Zhao et al.· Journal of NutriLife· 0 citations
Circulating tumor DNA currently functions mainly as a prognostic and response-associated biomarker in lung cancer immunotherapy, while its predictive, decision-defining role remains an important but investigational objective.
Yan Li, Guan-Yu Lu, Wei Song et al.· Frontiers in Immunology· 0 citations
The need for prospective validation and multidisciplinary collaboration to translate advances in radiomics, AI, liquid biopsy, airway classifiers, and multi-omics integration into clinically useful pathways that improve early lung cancer detection, reduce unnecessary interventions, and enhance patient outcomes is highl...
Yan Li, Guan-Yu Lu, Xiang-Liang Liu et al.· Critical reviews in oncology...· 0 citations
This review examines how tumor-derived signals activate IRE1α/XBP1 to upregulate both the autophagy-lysosome pathway (ALP) and ubiquitin-proteasome system (UPS); its crosstalk with inflammatory and metabolic networks; and the therapeutic potential of IRE1α inhibitors, XBP1-directed strategies, and nutritional approache...
Guan-Ran Ding, Wang Yang, Yi-Xin Zhao et al.· Biochimica et biophysica act...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
